

REMARKS/ARGUMENTS


In the Notification to Comply with Requirements for Patent Applications Containing Nucleotide and/or Amino Acid Sequence Disclosures mailed on March 3, 2008, the Office indicated that an amendment directing entry of the sequence listing into the application is required to place the application into conformance with the requirements of 37 CFR 1.821-1.825. In response, the specification has been amended herein to direct entry of the paper and computer-readable copies of the sequence listing being submitted concurrently herewith into the application.

Moreover, the specification has been amended at Table 1 with regard to SEQ ID NO:1 at P1' to replace "Lys" with --Arg--, thereby correcting an obvious error. It is respectfully submitted that support for the amendment to Table 1 may be found in the instant specification at claim 18 and, as such, it is respectfully submitted the amendment introduces no new matter. The paper and computer-readable copies of the sequence listing submitted herewith include this amendment to SEQ ID NO:1.

Should the Examiner have any questions concerning this response, the Examiner is respectfully invited to contact the undersigned at the telephone number set forth below.

The Commissioner is hereby authorized to charge payment of any fees associated with this communication, or credit any overpayment, to Deposit Account No. 08-2461. Such authorization includes authorization to charge fees for extensions of time, if any, under 37 C.F.R. §1.17 and also should be treated as a constructive petition for an extension of time in this reply or any future reply pursuant to 37 C.F.R. §1.136.

Respectfully submitted,


Andrea M. Wilkovich
Registration No.: 53,773

HOFFMANN & BARON, LLP
6900 Jericho Turnpike
Syosset, New York 11791
(973) 331-1700

TEMPLE-FIXED PEPTIDOMIMETICS AS MEDICAMENTS AGAINST HIV AND CANCER
 Application No. 10/550,778 Inventors: Zumbrunn et al. Docket No 753-54 PCT/US

ANNOTATED SHEET

83

Table 1: Examples 1-6, n = 4, n' = 6

Example	Seq.ID	P6'	P5'	P4'	P3'	P2'	P1'	Template	P1	P2	P3	P4	RT	Purity% ^a [M+ H]/2	
1	SEQ ID NO:1	Arg	Arg	2-Nal	Cys	Tyr	Tyr ^b Arg ^b ₁ Lys ^b Pro	Tyr	Cit	Cys	Arg-NH ₂	3.75	98	862.6	
2	SEQ ID NO:2	Arg	Arg	2-Nal	Cys	Tyr	Tyr ^b ₁ Lys ^b Pro	Tyr	Cit	Cys	Arg-NH ₂	3.87	96	876.3	
3	SEQ ID NO 3	Arg	Arg	2-Nal	Cys	Tyr	Tyr ^b ₁ Lys ^b Pro	Arg	Cit	Cys	Arg-NH ₂	3.28	97	858.4	
4	SEQ ID NO 4	Arg	Arg	2-Nal	Cys	Tyr	Tyr ^b ₁ Pro ^b Pro	Tyr	Arg	Cys	Arg-NH ₂	4.62	100	845.9	
5	SEQ ID NO:5	Arg	Arg	2-Nal	Cys	Tyr	Arg	^b Pro ^b Pro	Tyr	Arg	Cys	Arg-NH ₂	4.83	98	860.0
6	SEQ ID NO:6	Arg	Arg	2-Nal	Cys	Tyr	Arg	^b Lys ^b Pro	Tyr	Cit	Cys	Arg-NH ₂	4.10	96	875.9

a) %purity of compounds after prep. HPLC.

cysteines at position P3' and P3 are linked by a disulfide bridge